Does reducing cholesterol improve CAD survival?

Patient Care

Volumn 30, Issue 5, 1996, Pages 61-74

  Larosa, John C ^a  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842397435     PISSN: 0031305X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-1275.
2. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
3. Wong ND, Wilson PW, Kannel WB: Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Ann Intern Med 1991; 115:687-693.
4. Pekkanen J, Linn S, Heiss G, et al: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-1707.
5. LaRosa JC, Cleeman JI: Cholesterol lowering as a treatment for established coronary heart disease. Circulation 1992;85:1229-1235.
6. Blankenhorn DH, Nessim SA, Johnson RL, et al: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
7. Kane JP, Malloy MJ, Ports TA, et al: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
8. Buchwald H, Varco RL, Matts JP, et al: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-955.
9. Ornish D, Brown SE, Scherwitz LW, et al: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-133.
10. Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
11. Brown BG, Zhao XQ, Sacco DE, et al: Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J 1993;69:S48-S53.
12. Pearson TA, Marx HJ: The rapid reduction in cardiac events with lipid-lowering therapy: Mechanisms and implications. Am J Cardiol 1993;72:1072-1073.
13. Fuster V, Badimon L, Badimon JJ, et al: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-318.
14. Crouse JR III, Byington RP, Bond MG, et al: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995;75:455-459.
15. Furberg CD, Adams HP Jr, Applegate WB, et al: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-1687.
16. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al: Efficacy and safety of a new HWG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133.
17. Waters D, Higginson L, Gladstone P, et al: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Group. Circulation 1994;89:959-968.
18. MAAS Investigators: Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
19. Blankenhorn DH, Azen SP, Kramsch DM, et al: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
20. Gould AL, Rossouw JE, Santanello NC, et al: Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 1995;91:2274-2282.
21. Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
22. Sacks FM, Pasternak RC, Gibson CM, et al: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994;344:1182-1186.
23. Pyorala K, Pedersen TR, Kjekshus J: The effect of cholesterol lowering with simvastatin on coronary events in diabetic patients with coronary heart disease, abstract. Diabetes 1995;44(suppl I):35A.
24. Marts JP, Buchwald H, Fitch LL, et al: Subgroup analyses of the major clinical endpoints in the Program on the Surgical Control of the Hyperlipidemias (POSCH): Overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHD mortality or myocardial infarction. J Clin Epidemiol 1995;48: 389-405.
25. Udvarhelyi IS, Colditz GA, Rai A, et al: Cost-effectiveness and cost-benefit analyses in the medical literature: Are the methods being used correctly? Ann Intern Med 1992;116:238-244.
26. Goldman L, Weinstein MC, Goldman PA, et al: Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151.
27. Superko HR, Krauss RM: Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90:1056-1069.
28. Yusuf S, Zucker D, Peduzzi P, et al: Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists' Collaboration. Lancet 1994; 344:563-570.
29. Rossouw JE, Lewis B, Rifkind BM: The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-1119.
30. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27: 335-371.
31. Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-331.
32. Cohen MV, Byrne MJ, Levine B, et al: Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991;83:1294-1304.
33. Giles WH, Anda RF, Jones DH, et al: Recent trends in the identification and treatment of high blood cholesterol by physicians: Progress and missed opportunities. JAMA 1993;269:1133-1138.